SanBio Company Limited (4592.T)
JPY 2140.0
(7.0%)
JPY 2140.0
(7.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.78 Billion JPY | 34.66% |
| 2022 | -5.79 Billion JPY | -185.42% |
| 2021 | -2.03 Billion JPY | 76.04% |
| 2020 | -8.48 Billion JPY | 12.09% |
| 2019 | -9.64 Billion JPY | -14.57% |
| 2018 | -8.41 Billion JPY | -257.55% |
| 2017 | -2.35 Billion JPY | 44.74% |
| 2016 | -4.26 Billion JPY | 34.78% |
| 2015 | -6.53 Billion JPY | -22784.98% |
| 2014 | -28.55 Million JPY | 93.49% |
| 2013 | -438.6 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.35 Billion JPY | 11.35% |
| 2024 Q2 | -2.55 Billion JPY | 24.08% |
| 2023 Q2 | -3.82 Billion JPY | 20.57% |
| 2023 Q4 | -3.78 Billion JPY | -23.28% |
| 2023 FY | -3.78 Billion JPY | 34.66% |
| 2023 Q1 | -4.81 Billion JPY | 16.96% |
| 2023 Q3 | -3.07 Billion JPY | 19.64% |
| 2022 Q4 | -5.79 Billion JPY | -31.64% |
| 2022 Q3 | -4.4 Billion JPY | 27.0% |
| 2022 FY | -5.79 Billion JPY | -185.42% |
| 2022 Q2 | -6.03 Billion JPY | -81.9% |
| 2022 Q1 | -3.31 Billion JPY | -63.29% |
| 2021 FY | -2.03 Billion JPY | 76.04% |
| 2021 Q4 | -2.03 Billion JPY | 44.62% |
| 2021 Q2 | -5.09 Billion JPY | 23.76% |
| 2021 Q1 | -6.68 Billion JPY | 21.21% |
| 2021 Q3 | -3.66 Billion JPY | 27.97% |
| 2020 Q2 | -6.9 Billion JPY | 15.89% |
| 2020 FY | -8.48 Billion JPY | 12.09% |
| 2020 Q4 | -8.48 Billion JPY | -57.11% |
| 2020 Q3 | -5.39 Billion JPY | 21.86% |
| 2020 Q1 | -8.21 Billion JPY | 14.86% |
| 2019 FY | -9.64 Billion JPY | -14.57% |
| 2019 Q3 | -11.54 Billion JPY | 9.33% |
| 2019 Q4 | -9.64 Billion JPY | 16.44% |
| 2019 Q2 | -12.73 Billion JPY | -76.82% |
| 2019 Q1 | -7.2 Billion JPY | 14.47% |
| 2018 FY | -8.41 Billion JPY | -257.55% |
| 2018 Q4 | -8.41 Billion JPY | 8.9% |
| 2018 Q3 | -9.24 Billion JPY | 17.23% |
| 2018 Q2 | -11.16 Billion JPY | -151.27% |
| 2018 Q1 | -4.44 Billion JPY | -88.7% |
| 2017 Q1 | -3.19 Billion JPY | 24.98% |
| 2017 FY | -2.35 Billion JPY | 44.74% |
| 2017 Q4 | -2.35 Billion JPY | -14.71% |
| 2017 Q3 | -2.05 Billion JPY | 12.17% |
| 2017 Q2 | -2.33 Billion JPY | 26.89% |
| 2016 Q2 | -5.41 Billion JPY | 11.39% |
| 2016 FY | -4.26 Billion JPY | 34.78% |
| 2016 Q3 | -4.76 Billion JPY | 12.12% |
| 2016 Q1 | -6.11 Billion JPY | 6.4% |
| 2016 Q4 | -4.26 Billion JPY | 10.52% |
| 2015 Q2 | -7.25 Billion JPY | 3.55% |
| 2015 Q1 | -7.52 Billion JPY | -26255.13% |
| 2015 Q4 | -6.53 Billion JPY | 7.28% |
| 2015 FY | -6.53 Billion JPY | -22784.98% |
| 2015 Q3 | -7.04 Billion JPY | 2.89% |
| 2014 FY | -28.55 Million JPY | 93.49% |
| 2014 Q4 | -28.55 Million JPY | 0.0% |
| 2013 FY | -438.6 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 610.221% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | -234.207% |
| GNI Group Ltd. | -17.93 Billion JPY | 78.868% |
| Linical Co., Ltd. | -4.46 Billion JPY | 15.091% |
| Trans Genic Inc. | -221.16 Million JPY | -1613.493% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 13.753% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 20.883% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 364.361% |
| AnGes, Inc. | -3.79 Billion JPY | 0.212% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -800.583% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 115.215% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -660.752% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -712.639% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | -40.042% |
| CanBas Co., Ltd. | -1.88 Billion JPY | -100.705% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | -285.862% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | -11.56% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | -266.314% |
| Kidswell Bio Corporation | 343.58 Million JPY | 1202.979% |
| PeptiDream Inc. | 3.29 Billion JPY | 215.119% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | -289.651% |
| Ribomic Inc. | -2.09 Billion JPY | -80.485% |
| Healios K.K. | -2.19 Billion JPY | -73.046% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | -301.088% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | -44.417% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | -167.435% |
| StemRIM | -8.41 Billion JPY | 54.938% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 19.083% |
| FunPep Company Limited | -1.79 Billion JPY | -111.317% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | -77.38% |
| Stella Pharma Corporation | -1.11 Billion JPY | -238.548% |
| TMS Co., Ltd. | -3.44 Billion JPY | -9.954% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 31.787% |
| Cuorips Inc. | -5.56 Billion JPY | 31.852% |
| K Pharma,Inc. | -3.26 Billion JPY | -16.021% |
| Takara Bio Inc. | -32.2 Billion JPY | 88.232% |
| ReproCELL Incorporated | -2.93 Billion JPY | -28.943% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -473.365% |
| StemCell Institute Inc. | -2.83 Billion JPY | -33.593% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | -83.402% |
| CellSeed Inc. | -2.01 Billion JPY | -88.352% |